 Braxia Scientific Corp has reported encouraging preliminary findings of a recent clinical study that suggests ketamine may be as effective as a standalone antidepressant, versus as an adjunctive therapy. The Toronto-based company said the study showed comparable clinical benefits such as antidepressant effects and reduction in suicidal thoughts in a large sample of 220 patients with treatment-resistant depression TRD who received intravenous ketamine infusions as a monotherapy, as compared with those receiving ketamine in addition to oral antidepressants. 